Arcum Vision develops novel ophthalmic antimicrobial therapeutics to combat rising antimicrobial resistance in eye infections. Their focus is on creating next-generation treatments for physicians to address unmet clinical needs in ophthalmology.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of patients worldwide suffer from vision-threatening ocular infections annually. A high percentage of these infections are resistant to currently available FDA-approved antibiotics, leading to the use of off-label treatments with limited efficacy. The development of new ophthalmic antimicrobial drugs has been slow, with only one new antibiotic approved in the last 20 years.
Solution
Arcum Vision is developing a portfolio of novel ophthalmic antimicrobial therapeutics designed to combat the increasing rates of antimicrobial resistance in ocular infections. Their lead technology, AV2019F2 Ophthalmic Solution, is a patented formulation combining Polymyxin B, Trimethoprim, and Rifampin. This formulation represents a potential breakthrough in treating blinding corneal infections by providing a more effective solution against resistant strains. Arcum Vision aims to equip physicians with next-generation antimicrobial therapeutics to address unmet clinical needs in ophthalmology and save vision.
Target Audience
The primary target audience includes ophthalmologists and other physicians treating patients with vision-threatening ocular infections, as well as hospitals and eye care clinics.
Features
- AV2019F2: A novel ophthalmic formulation combining Polymyxin B, Trimethoprim, and Rifampin.
- Designed to combat multi-drug resistant ocular infections, including MRSA.
- Addresses the need for more effective treatments in the face of rising antibiotic resistance.